Sight Sciences reports Q1 2026 earnings today with the stock up 22% over the past month — but analysts still deeply divided on whether that rally reflects genuine fundamental recovery or gets ahead of the evidence.
The price rebound tells a striking story. After a brutal March 4 print that sent the stock down nearly 25% in a single session and almost 30% over the following five days, shares have climbed back to $4.30. That is still well below where they started the year, but the one-week gain of 8% and one-month surge of 22% signal that some buyers stepped back in aggressively. The March event result underscores how violent the downside reactions have been: the prior quarter also saw a 3% initial bounce that faded to a 7% loss over five days. Short interest is a non-story here — at just 2.1% of the free float with cost to borrow running below 1.5% and lending conditions extremely loose, there is no meaningful short pressure going into the number.
Options positioning has grown marginally more defensive ahead of the print. The put/call ratio moved up to 0.21, roughly one standard deviation above its 20-day average of 0.12 — a mild shift toward protection, but far from an alarm signal. The 52-week range stretches from near zero to 1.44, which puts the current reading firmly in low-hedging territory despite the recent tick higher.
The analyst debate centres on two things: the trajectory of the TearCare dry-eye system and the pace of decline in the Surgical Glaucoma segment. Bulls note that analysts maintained full-year 2025 and 2026 revenue projections at $75 million and $82 million respectively, and point to MIGS market-share gains as a structural driver. UBS kept a Buy rating as recently as early March, though it trimmed its target to $11. Stifel moved the other direction in early March, raising its target to $8. Bears lean on the company's own guidance for mid-single-digit year-over-year declines in Surgical Glaucoma, persistent cash burn, and delayed insurance coverage for TearCare. Citigroup, maintaining a Neutral, cut its target from $9.10 to $6.50 on the same day — a sharp divergence from the UBS read. The consensus mean target of $8.34 implies nearly double the current price, but that gap reflects genuine disagreement, not confidence. Analyst data dates to early April; no major moves have been published since.
On the ownership side, founders Paul and David Badawi — who together hold more than 13% of the company — both sold small amounts in early April at prices around $3.50, a level now below the current price. The sells were modest in dollar terms (under $200,000 combined) and carry low trade significance scores, but the timing at depressed levels is worth flagging. BlackRock and Vanguard both added to positions in the most recent quarter, providing a degree of institutional support.
Today's print is the first quarterly report following two consecutive sharp post-earnings declines, and it will test whether the revenue-recovery thesis that drove the spring rally has any actual data behind it — or whether the Q1 numbers reinstate the bear case.
See the live data behind this article on ORTEX.
Open SGHT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
